Literature DB >> 10473521

A reverse-sandwich enzyme-linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera.

H Miyazawa1, H Bannai, T Yanase, C Morita, S Satoh, J Sugiyama, S Taniguchi, S Inouye.   

Abstract

A reverse-sandwich enzyme-linked immunosorbent assay (ELISA), in which an antibody is sandwiched by antigens, was established for the titration of antibodies to verocytotoxins (VT) in human and animal sera. This assay has two advantages over a conventional indirect ELISA: (i) higher specificity and sensitivity and (ii) the ability to comparably titrate antibodies from different species. The VT1 (Shiga-like toxin 1) antibody-positive rates were 5% in 202 normal adult humans and 99% in 93 normal cattle at a dairy farm. This ELISA is most suitable for seroepidemiologic studies of infections with VT-producing Escherichia coli in humans and various animal species.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10473521      PMCID： PMC95758          DOI： 10.1128/CDLI.6.5.701-704.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  11 in total

1.  Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from Escherichia coli O157:H7.

Authors:  H Ito; T Yutsudo; T Hirayama; Y Takeda
Journal:  Microb Pathog       Date:  1988-09       Impact factor: 3.738

2.  A reverse-type sandwich enzyme-linked immunosorbent assay for detecting antibodies to Borna disease virus.

Authors:  T Horimoto; H Takahashi; M Sakaguchi; K Horikoshi; S Iritani; H Kazamatsuri; K Ikeda; M Tashiro
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  A reverse-sandwich ELISA for IgG antibody to a pollen allergen.

Authors:  H Miyazawa; S Inouye; M Sakaguchi; K Koizumi
Journal:  J Allergy Clin Immunol       Date:  1988-09       Impact factor: 10.793

4.  Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Authors:  D Reymond; R P Johnson; M A Karmali; M Petric; M Winkler; S Johnson; K Rahn; S Renwick; J Wilson; R C Clarke; J Spika
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

5.  Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group.

Authors:  A Caprioli; I Luzzi; F Rosmini; P Pasquini; R Cirrincione; A Gianviti; M C Matteucci; G Rizzoni
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

6.  Rapid detection of herpes simplex virus in clinical specimens by use of a capture biotin-streptavidin enzyme-linked immunosorbent assay.

Authors:  L S Nerurkar; M Namba; G Brashears; A J Jacob; Y J Lee; J L Sever
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

7.  Protection against verocytotoxin in mice induced by liposome-coupled verocytotoxin.

Authors:  S Naito; A Horino; T Komiya; Y Fukuda; M Takahashi; Y Ami; Y Suzaki; S Satoh; F Gondaira; J Sugiyama; Y Nakano; M Mori; K Awai; S Nishinohara; K Komuro; T Uchida
Journal:  Int Arch Allergy Immunol       Date:  1997-11       Impact factor: 2.749

8.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

9.  Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1.

Authors:  M A Karmali; M Petric; M Winkler; M Bielaszewska; J Brunton; N van de Kar; T Morooka; G B Nair; S E Richardson; G S Arbus
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

10.  Detection of verocytotoxin from stool and serological testing of patients with diarrhea caused by Escherichia coli O157 : H7.

Authors:  S Yamada; S Matsushita; A Kai; M Sasaki; A Tsuji; T Kanemitsu; N Yamashita; E Anzai; Y Kudoh
Journal:  Microbiol Immunol       Date:  1993       Impact factor: 1.955
View more
  6 in total

1.  A quantitative ELISA for monitoring the secretion of ZZ-fusion proteins using SpA domain as immunodetection reporter system.

Authors:  F J Mergulhão; G A Monteiro; J M Cabral; M A Taipa
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

2.  Development and application of a double-antigen sandwich enzyme-linked immunosorbent assay for detection of antibodies to porcine circovirus 2.

Authors:  Meng Ge; Wei Luo; Daliang Jiang; Runcheng Li; Wenwei Zhao; Guoliang Chen; Xingdong Yang; Xinglong Yu
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

3.  Immune Response in Calves Vaccinated with Type Three Secretion System Antigens and Shiga Toxin 2B Subunit of Escherichia coli O157:H7.

Authors:  Luisina Martorelli; Sergio Garbaccio; Daniel A Vilte; Adriana A Albanese; María P Mejías; Marina S Palermo; Elsa C Mercado; Cristina E Ibarra; Angel A Cataldi
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

4.  Construction of an HRP-streptavidin bound antigen and its application in an ELISA for porcine circovirus 2 antibodies.

Authors:  Meng Ge; Run-Cheng Li; Tailong Qu; Wenjie Gong; Xing-Long Yu; Changchun Tu
Journal:  AMB Express       Date:  2017-09-18       Impact factor: 3.298

5.  Reverse ELISA for the detection of anti West Nile virus IgG antibodies in humans.

Authors:  D Ludolfs; M Niedrig; J T Paweska; H Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 5.103

6.  Performance Evaluation of a Prototype Architect Antibody Assay for Babesia microti.

Authors:  Kevin Cheng; Kelly E Coller; Christopher C Marohnic; Zachary A Pfeiffer; James R Fino; Randee R Elsing; Janet Bergsma; Marilee A Marcinkus; Alak K Kar; Orlando H Gumbs; Kathy S Otis; Jeffrey Fishpaugh; Phillip W Schultz; Mark R Pope; Alfredo R Narvaez; Susan J Wong; Susan Madison-Antenucci; Thomas P Leary; George J Dawson
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.